Loading news...
NEW YORK, Jan. 8, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Waldencast plc ("Waldencast" or the "Company") (NASDAQ: WALD). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
NEW YORK, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Waldencast plc (“Waldencast” or the “Company”) (NASDAQ: WALD). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
NEW YORK, Jan. 1, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Waldencast plc ("Waldencast" or the "Company") (NASDAQ: WALD). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
NEW YORK, Dec. 30, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Waldencast plc (“Waldencast” or the “Company”) (NASDAQ: WALD). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
NEW YORK , Dec. 11, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Waldencast plc ("Waldencast" or the "Company") (NASDAQ: WALD). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
U.S. stock futures were higher this morning, with the Nasdaq futures gaining around 100 points on Monday.
Obagi® saypha® ChIQ™ data selected as a top 10 cosmetic oral abstract presentation Obagi® saypha® ChIQ™ data selected as a top 10 cosmetic oral abstract presentation
NEW YORK, Nov. 14, 2025 (GLOBE NEWSWIRE) -- Waldencast plc, (NASDAQ: WALD) (“Waldencast” or the “Company”), a global multi-brand beauty and wellness platform, today announced that it had sold its rights to the “Obagi” trademark in Japan to Rohto Pharmaceutical Co., Ltd. (“Rohto”) for USD $82.5 million.
First Half Fiscal 2025 Results and Q3 2025 Financial Results Expected to be Reported on November 24, 2025 First Half Fiscal 2025 Results and Q3 2025 Financial Results Expected to be Reported on November 24, 2025
A Next-Generation, Redensifying Scalp Serum Clinically Proven to Promote Fuller, Denser-Looking Hair* A Next-Generation, Redensifying Scalp Serum Clinically Proven to Promote Fuller, Denser-Looking Hair*
U.S. Launch Planned in 2026 and Positions Obagi Medical as a Leading Dermatological Megabrand at the Convergence of Integrated Skincare and Aesthetics While Doubling its Addressable Market U.S. Launch Planned in 2026 and Positions Obagi Medical as a Leading Dermatological Megabrand at the Convergence of Integrated Skincare and Aesthetics While Doubling its Addressable Market
Obagi Medical delivers H1 2025 double-digit growth in its Core Strategic Channels. Novaestiq Acquisition Doubles the Brand's Addressable Market in the U.S.
Acquisition strengthens Obagi Medical's product portfolio with proven, scientifically backed, injectable portfolio New products position Obagi Medical at the forefront of health, beauty and aesthetics convergence LONDON, July 23, 2025 (GLOBE NEWSWIRE) -- Waldencast plc (NASDAQ: WALD) (“Waldencast”), a global multi-brand beauty and wellness platform, today announced that it has acquired Novaestiq Corp. (Novaestiq), a growth-oriented aesthetic and medical dermatological innovations company, as well as the U.S. rights to the Saypha® line of hyaluronic acid (HA) injectable gels. The strategic acquisition expands Obagi Medical's offerings beyond U.S. medical-grade skincare, a market projected to be $2.2 billion by 2029, into the growing U.S. dermal filler market, projected to reach $2 billion in market size by 2029, effectively doubling its addressable market.1 The move marks a pivotal step in positioning Obagi Medical as an industry leader in integrated skincare and aesthetic solutions.
Squarepoint Ops LLC decreased its stake in Waldencast plc (NASDAQ:WALD – Free Report) by 82.6% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 16,600 shares of the company’s stock after selling 78,847 shares during the period. Squarepoint Ops LLC’s holdings in Waldencast were worth $67,000 as of its most recent SEC filing. Several other institutional investors and hedge funds also recently modified their holdings of the stock. Barclays PLC boosted its holdings in Waldencast by 15.1% in the fourth quarter. Barclays PLC now owns 37,342 shares of the company’s stock valued at $150,000 after purchasing an additional 4,906 shares during the last quarter. SG Americas Securities LLC purchased a new position in Waldencast in the fourth quarter valued at about $42,000. Northern Trust Corp boosted its holdings in Waldencast by 4.1% in the fourth quarter. Northern Trust Corp now owns 167,662 shares of the company’s stock valued at $674,000 after purchasing an additional 6,640 shares during the last quarter. Ethic Inc. purchased a new position in Waldencast in the fourth quarter valued at about $56,000. Finally, Wells Fargo & Company MN boosted its holdings in Waldencast by 29.9% in the fourth quarter. Wells Fargo & Company MN now owns 14,571 shares of the company’s stock valued at $59,000 after purchasing an additional 3,358 shares during the last quarter. Hedge funds and other institutional investors own 41.97% of the company’s stock. Waldencast Stock Down 0.9% NASDAQ WALD opened at $2.30 on Wednesday. The company has a quick ratio of 0.78, a current ratio of 1.47 and a debt-to-equity ratio of 0.21. The stock’s 50 day moving average is $2.56 and its two-hundred day moving average is $3.06. Waldencast plc has a 1-year low of $1.98 and a 1-year high of $4.74. Analysts Set New Price Targets Several brokerages recently issued reports on WALD. Canaccord Genuity Group cut their price target on Waldencast from $6.00 to $5.00 and set a “buy” rating on the stock in a report on Thursday, May 15th. Wall Street Zen downgraded Waldencast from a “hold” rating to a “sell” rating in a report on Thursday, May 22nd. Telsey Advisory Group cut their price target on Waldencast from $5.00 to $4.00 and set an “outperform” rating on the stock in a report on Thursday, May 15th. Industrial Alliance Securities set a $5.00 price target on Waldencast in a report on Tuesday, April 22nd. Finally, Alliance Global Partners reissued a “buy” rating on shares of Waldencast in a report on Thursday, May 15th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and five have assigned a buy rating to the stock. According to data from MarketBeat.com, Waldencast presently has an average rating of “Moderate Buy” and a consensus price target of $5.11. View Our Latest Stock Report on Waldencast Waldencast Company Profile (Free Report) Waldencast plc operates in the beauty and wellness business. The company engages in developing, acquiring, accelerating, and scaling various brands. It provides cosmetic, over-the-counter, and prescription products under the Obagi Medical, Obagi Clinical, and Obagi Professional brands; and a Skintrinsiq device for use in facial treatments that is used by physicians' offices, spas, and aestheticians. Read More Five stocks we like better than Waldencast The 3 Best Blue-Chip Stocks to Buy Now AppLovin Dips on S&P 500 Snub, Morgan Stanley Lifts Target Anyway Most Volatile Stocks, What Investors Need to Know Casey’s Surges on Strong Q4, More Gains Likely Ahead Health Care Stocks Explained: Why You Might Want to Invest Government Mandate Sends eVTOL Stocks Flying
Waldencast is a fast-growing beauty company with strong brands (Milk Makeup, Obagi), but faces margin pressure and negative earnings due to high SG&A and debt. Recent revenue growth remains solid, but Q1 FY25 saw a sales dip, especially in Milk Makeup, due to international headwinds and inventory adjustments. The company's financials are typical for a high-growth firm: negative cash flow, high leverage, but manageable liquidity, and a long debt runway until 2030.
Waldencast plc (NASDAQ:WALD ) Q1 2025 Earnings Conference Call May 14, 2025 8:30 AM ET Company Participants Allison Malkin - Partner ICR, Investor Relations Michel Brousset - Founder & Chief Executive Officer Manuel Manfredi - Chief Financial Officer Conference Call Participants John Chapman - Alliance Global Partners Jonna Kim - TD Cowen Operator Good day, and welcome to the Waldencast First Quarter 2025 Earnings Call. All participants will be in listen-only mode.
Q1 Net Revenue of $65.4 million, (4.1)% decline from Q1 202476.4% Adjusted Gross Margin, an improvement of 10 basis points$4.4 million of Adjusted EBITDA
LONDON, May 06, 2025 (GLOBE NEWSWIRE) -- Waldencast plc, (NASDAQ: WALD) (“Waldencast”), a global multi-brand beauty and wellness platform provided the details for its First Quarter Fiscal 2025 conference call and webcast. As previously announced, the Company will issue its First Quarter Fiscal 2025 results on May 13, 2025 after the close of the U.S. market.
A Scientific Breakthrough in Skin Renewal: A Clinically Proven Dual-Action, Slow-Release, Overnight Skin Renewal Cream for a Resurfaced, Smoother, and More Even-Looking Complexion
Waldencast plc (NASDAQ:WALD ) Q4 2024 Earnings Conference Call March 19, 2025 8:30 AM ET Company Participants Allison Malkin - Investor Relations Michel Brousset - Founder and Chief Executive Officer Manuel Manfredi - Chief Financial Officer Conference Call Participants Jonna Kim - TD Cowen Ashley Helgans - Jefferies Linda Bolton Weiser - D.A. Davidson Olivia Tong - Raymond James Operator Greetings, welcome to the Waldencast Fourth Quarter and Fiscal Year 2024 Earnings Call.